Anzeige
Mehr »
Login
Samstag, 23.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Microsofts, Googles und Amazons nukleares Wettrennen macht diese Uranaktie zu einem Muss!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
206 Leser
Artikel bewerten:
(0)

BioDerm Announces New Partnership with CellMark Medical, a Division of CellMark AB

Finanznachrichten News

LARGO, Florida, Jan. 27, 2017 /PRNewswire/ --Today BioDerm®, Inc. announced the launch of their new partnership with CellMark Medical to bring the next generation of urinary management, securement and skin protection devices into select Asian markets. BioDerm, Inc. is the manufacturer of the Men's Liberty' and Safe n'Dry® Male Urinary Devices, the next generation hydrocolloid-based external catheters that reduce the risk of developing urinary tract infections commonly associated with indwelling catheters1 and provide a safe, skin-friendly seal for 24 hours or more. Because of their occlusive seal and noninvasive design, they reduce the risk of catheter associated urinary tract infections, or CAUTIs, and skin macerations and injuries associated with the use of adult diapers or condom catheters when used for incontinence2. In addition, BioDerm's CathGrip® line of medical device securement products can reduce the instances of Medical Device-Related Hospital Acquired Pressure Ulcers (HAPUs).

BioDerm_Logo

"We are excited to be working with CellMark Medical to improve the quality of care that Asian patients receive in hospitals today. We look forward to explosive growth in highly populous markets that have increasing standards of care and wealth," says BioDerm's President, Gaet Tyranski.

"CellMark Medical was formed to cost effectively bring innovative medical devices and pharmaceutical products to the world to improve quality of life. We are pleased to partner with BioDerm to bring their unique and effective products to select Asian markets, using our proprietary trade platform, where we have an established network of distributors with broad access to end users," says CellMark Medical's President, Niclas Mottus Olsson.

Headquartered in Largo, Florida, BioDerm is one of the nation's leading manufacturers of proprietary hydrocolloid products for urinary management, securement, infection control and skin protection. The company challenges accepted inferior standards of care by creating products that reduce infection rates, reduce pressure injuries, add comfort and reliability, and vastly improve quality of life. Our products are sold world-wide and our brands include Men's Liberty', Safe n'Dry®, CathGrip®, BioPlus+' and FreeDerm'. You can find more info here: http://www.bioderminc.com

Headquartered in Gothenburg, Sweden, CellMark Medical leverages an expert global trading infrastructure, with a network across 120 markets, to simplify the exporting process and minimize associated risks, allowing MedTech manufacturers transparent control of their international sales operations. CellMark Medical sources qualified, trusted and well-established distribution partners in chosen markets. CellMark offers producers and end-users all manner of sales and marketing services, timely, accurate market information, risk management, order tracking, invoicing and trade documentation, all of which contribute to world-class medical device supply chain service operations. CellMark Medical manages marketing literature and packaging design, development and implementation in local markets. CellMark Medical coordinates the regulatory approval process in the local market, ensuring the necessary documents are comprehensively vetted and delivered to the correct authorities in a timely manner, leveraging an in-depth network of experts to quickly overcome any local obstacles. CellMark provides Trademark registration services and applies for and holds product registrations locally, on behalf of the product owner. The licenses can be transferred back at any time to ensure the manufacturer has full control of the future of their business. More information can be found here: http://www.cellmark.com/divisions-business-units/medical/

1May/June2016;43(3):301-307. Published by Lippincott Williams & Wilkins
External Collection Devices as an Alternative to the Indwelling Urinary Catheter
Evidence-Based Review and Expert Clinical Panel Deliberations
Mikel Gray, Claudia Skinner, Wendy Kaler

2 http://www.hospimedica.com/critical-care/articles/294748243/male-urinary-device-addresses-patient-management-challenges.html

Contact: Wendy LaTorre
BioDerm, Inc.
12320 73rd Ct. N, Largo, FL 33773 USA
+1(727)800-1976
wlatorre@bioderminc.com

Logo - http://mma.prnewswire.com/media/462295/BioDerm_Logo.jpg

© 2017 PR Newswire
Nach Nvidia: 5 KI-Revolutionäre aus der zweiten Reihe!
Künstliche Intelligenz hat spätestens nach dem Raketenstart von Chat GPT das Leben aller verändert. Doch der Superzyklus steht nach Meinungen von Experten erst am Anfang. Während Aktien wie Nvidia von der ersten Aufwärtsentwicklung stark profitieren konnten, versprechen aussichtsreiche Player aus der

zweiten Reihe noch enormes Aufwärtspotenzial.

Im kostenlosen, exklusiven Spezialreport präsentieren wir ihnen 5 innovative KI-Unternehmen, die bahnbrechende Entwicklungen in diesem Sektor prägen könnten.

Warum sollten Sie dabei sein?
Trotz der jüngsten Erfolge steht die Entwicklung der künstlichen Intelligenz noch am Beginn eines neuen Superzyklus. Experten gehen davon aus, dass der Sektor bis 2032 global auf 1,3 Billionen US-Dollar explodieren wird, wobei ein großer Teil auf Hardware und Infrastruktur entfallen wird.

Nutzen Sie die Chance!
Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche 5 KI-Aktien das größte Potenzial zur Vervielfachung besitzen. Dieser Report ist komplett kostenlos und zeigt Ihnen die aussichtsreichsten Investments im KI-Sektor.
Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.